
Does Cagrilintide Preserve Muscle? What Human Studies Show


Human research has not established that cagrilintide reliably preserves muscle or protects it better than GLP-1 treatment. The CagriSema body-composition substudy measured losses of both fat and lean soft tissue; it did not isolate cagrilintide's contribution or directly measure all of that lean-tissue change as skeletal muscle. Animal and cell findings help generate questions, but patients and athletes need evidence about human strength and function as well.
At Maryland Trim Clinic, our medical weight loss program considers health and function alongside weight. A treatment plan should support adequate nutrition and activity, with reassessment when weakness or eating difficulty appears.
Lean mass is not the same as muscle
Body composition methods divide the body into measured or estimated compartments. Lean soft tissue includes more than skeletal muscle, including water and organs. Fat-free mass is another related term and can include bone mineral depending on the measurement and reporting convention.
This distinction matters when interpreting a headline. A reduction in lean tissue is not a direct measurement of muscle protein lost. At the same time, calling a change merely lean mass does not mean it is irrelevant. The amount, context, method, and accompanying function need consideration.
Strength, mobility, fatigue, and ability to perform normal activities add information that a compartment estimate cannot supply. A person can lose weight and move more easily while still needing attention to nutrition or strength. These outcomes should be evaluated together.
What human CagriSema body-composition data show
The REDEFINE 1 publication included a prespecified DXA body composition assessment in 252 of 3,417 participants. In the CagriSema group, estimated decreases at 68 weeks included 17.0 kilograms of fat mass and 8.4 kilograms of lean soft tissue under the trial-product analysis. The report characterized the composition of loss as approximately 67% fat and 33% lean soft tissue.
These findings concern cagrilintide plus semaglutide, a defined subset, and a specific measurement approach. They do not show zero lean tissue loss. They also do not establish that the lean tissue change was entirely skeletal muscle or that cagrilintide alone produced a protective effect.
The trial reported improved participant-rated physical function, illustrating that body composition and function can change in different ways. A complete interpretation should consider both rather than selecting only the measure that supports a favorable or alarming narrative.
Why animal and cell studies do not prove muscle preservation
Preclinical research has explored cagrilintide's effects on food intake, fat, and lean tissue in rodents. Those experiments help investigate mechanisms under controlled conditions. Their species, exposure, diet, and measurement methods differ from human treatment.
A finding that a mouse retained lean tissue cannot establish that an older adult, recreational athlete, or person with chronic disease will retain muscle under the same named drug. Human studies need to assess the relevant outcome directly.
The same caution applies to comparisons with other amylin agents. A favorable animal comparison does not establish a clinical ranking, and a biochemical hypothesis about protein metabolism is not proof of better strength or recovery in patients.
A 2026 laboratory study tested semaglutide, tirzepatide and cagrilintide in cultured mouse and human muscle cells. It examined mitochondrial responses over hours and days. Human cells in a dish are not a clinical trial in people: the study did not establish muscle retention, better strength, athletic recovery or a cagrilintide performance advantage.
Relative proportions can improve while absolute lean tissue falls
In a simplified hypothetical example, someone starts at 100 kilograms with 60 kilograms classified as lean tissue. After losing weight, they weigh 80 kilograms with 52 kilograms of lean tissue. Their lean proportion rises from 60% to 65%, even though the absolute lean amount falls by 8 kilograms. The example illustrates the denominator; it is not an actual trial result or a prediction.
That is why a claim such as improved body composition needs its denominator. Does it mean less fat overall, a better fat-to-lean ratio, unchanged lean mass, or improved physical performance? Those are different outcomes.
Avoid comparing percentages from different measurement methods as though they were identical. DXA, MRI, bioelectrical impedance, and external body-shape estimates answer different questions and have different limitations. Consistency and appropriate interpretation matter more than collecting many numbers without a clear purpose.
What would establish a muscle-preservation advantage?
A persuasive human study would identify the exact treatment and comparator, use suitable measures of muscle and function, and follow participants for an appropriate duration. Nutrition, activity, baseline health, and the amount of weight lost would need consideration because they can influence body composition.
The study would also need to distinguish a drug-specific effect from differences in total weight change or participant characteristics. A small subgroup or exploratory analysis may be useful, but it should be labeled accordingly and confirmed where needed.
Until those questions are answered, statements that cagrilintide spares muscle better than all GLP-1 medicines are too broad. The claim is especially inappropriate when used to encourage unsupervised use of an investigational product.
Supporting strength during established weight treatment

The joint advisory on nutrition during GLP-1 therapy emphasizes nutritional assessment and the importance of activity, including resistance training, as part of care. The details should be individualized rather than reduced to a universal calorie or protein target.
Protein needs can depend on age, health, kidney status, activity, and other factors. Adequate total intake and food variety also matter. A supplement alone does not guarantee preservation of muscle, particularly if the overall eating pattern is inadequate.
Resistance exercise should fit the person's ability and medical circumstances. Someone with pain, frailty, or a new limitation may need adapted activity or additional professional input. More exercise is not automatically the right response to unexplained weakness or poor intake.
Our nutritional counseling and coaching can help connect these priorities with practical meals and routines. The aim is a sustainable plan that supports function during weight change.
Tracking without overinterpreting measurements
Use a consistent weight trend and a small set of relevant functional observations. Our weight tracking guide can help reduce confusion from ordinary fluctuations. Note changes in usual activities, strength, fatigue, and recovery that matter to you.
Our 3D body scanning service follows body shape and circumference estimates. It should not be used as proof that a drug preserved skeletal muscle or as a substitute for a clinical assessment of muscle weakness.
Similarly, a resting metabolic rate assessment measures resting energy expenditure under test conditions. It cannot determine by itself how much muscle was lost or identify the best investigational medicine for preserving it.
When to review the plan
Persistent weakness, difficulty eating, repeated vomiting, or inability to maintain hydration deserves attention. A falling scale number does not make those symptoms acceptable. Severe abdominal pain or signs of significant dehydration need prompt assessment.
If progress slows, our plateau guide can help organize a broader review. A plateau does not establish that muscle has been lost or that another receptor-targeting drug needs to be added.
Our GLP-1 treatment information can help frame a discussion of established options. Cagrilintide remains investigational, and an article about its research does not imply that it is available as routine treatment or offered at our clinic.
A useful goal for patients and athletes
Define success using the outcomes that matter: health, function, adequate nourishment, and a manageable treatment burden. Body composition may be one part of that assessment, but a drug should not be selected from an unsupported muscle-sparing label.
To discuss your concerns, contact Maryland Trim Clinic. Bring any body composition reports, the measurement method, and changes in strength or daily activity so the numbers can be interpreted in context.
Frequently Asked Questions
Does a higher lean-mass percentage mean no lean tissue was lost?
No. The proportion can rise if fat decreases faster, even while the absolute amount of lean tissue falls. Check both the amount and the percentage.
Do CagriSema results prove that cagrilintide alone protects muscle?
No. Combination findings cannot isolate one component's contribution, and lean soft tissue is not identical to skeletal muscle.
Can protein supplements guarantee muscle preservation?
No. Overall nutrition, appropriate activity, health conditions, and the treatment plan all matter. Intake targets should be individualized.
Should athletes use cagrilintide because of animal lean-mass findings?
Animal results do not establish safety or a human performance advantage. Cagrilintide remains investigational and should not be self-selected for that purpose.
Talk through body composition questions
Bring your reports and questions to a consultation so we can review them in context and discuss appropriate next steps.